S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
Log in

NASDAQ:ELGX - Endologix Stock Price, Forecast & News

$1.55
-0.01 (-0.64 %)
(As of 01/28/2020 02:18 PM ET)
Today's Range
$1.54
Now: $1.55
$1.65
50-Day Range
$1.55
MA: $1.89
$2.24
52-Week Range
$1.55
Now: $1.55
$8.30
Volume5,829 shs
Average Volume222,468 shs
Market Capitalization$27.81 million
P/E RatioN/A
Dividend YieldN/A
Beta0.19
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.47 million
Book Value$3.83 per share

Profitability

Net Income$-79,710,000.00

Miscellaneous

Employees528
Market Cap$27.81 million
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.


Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

When did Endologix's stock split? How did Endologix's stock split work?

Endologix shares reverse split on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) issued its quarterly earnings results on Wednesday, November, 6th. The medical instruments supplier reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.08. The medical instruments supplier earned $35.78 million during the quarter, compared to analyst estimates of $35.26 million. Endologix had a negative net margin of 58.24% and a negative return on equity of 99.62%. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Endologix.

What price target have analysts set for ELGX?

3 analysts have issued 1-year price targets for Endologix's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endologix's stock price to reach $7.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price. View Analyst Price Targets for Endologix.

What is the consensus analysts' recommendation for Endologix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.

Has Endologix been receiving favorable news coverage?

Press coverage about ELGX stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Endologix earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View News Stories for Endologix.

Are investors shorting Endologix?

Endologix saw a drop in short interest in December. As of December 13th, there was short interest totalling 655,300 shares, a drop of 5.8% from the November 28th total of 695,400 shares. Based on an average trading volume of 163,900 shares, the days-to-cover ratio is presently 4.0 days. Approximately 4.3% of the company's stock are sold short. View Endologix's Current Options Chain.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $1.54.

How big of a company is Endologix?

Endologix has a market capitalization of $27.63 million and generates $156.47 million in revenue each year. The medical instruments supplier earns $-79,710,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. Endologix employs 528 workers across the globe.View Additional Information About Endologix.

What is Endologix's official website?

The official website for Endologix is http://www.endologix.com/.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  447 (Vote Underperform)
Total Votes:  899
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel